There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Supernus Pharmaceuticals (NASDAQ: SUPN) and Aquinox Pharmaceuticals (NASDAQ: AQXP) with bullish sentiments.
Supernus Pharmaceuticals (NASDAQ: SUPN)
In a report released today, David Buck from B.Riley FBR reiterated a Buy rating on Supernus Pharmaceuticals (NASDAQ: SUPN), with a price target of $68. The company’s shares opened today at $57.15, close to its 52-week high of $57.95.
Buck wrote:
“We update our model with some modest EPS estimate increases in 2018 and 2019 of $0.10 and $0.05 to $2.00 and $2.80 respectively. We expect Supernus (SUPN) to remain a high- growth company and we roll forward our valuation to 2019; we raise our price target from $54 per share to $68. Our new EPS forecasts represent 87% Y/Y growth for 2018 and 40% growth for 2019. Additionally, we expect the company to release key pivotal data for its pipeline drugs SPN-812 (non-stimulant ADHD) and SPN-810 (impulsive aggression) by 1Q19 and an investigator-sponsored trial for Oxtellar XR in bipolar disorder should be fully enrolled by end of 2018.”
According to TipRanks.com, Buck is a 4-star analyst with an average return of 14.6% and a 72.9% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Amag Pharmaceuticals.
Currently, the analyst consensus on Supernus Pharmaceuticals is Strong Buy and the average price target is $51.25, representing a -10.3% downside.
In a report issued on May 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $55 price target.
See today’s analyst top recommended stocks >>
Aquinox Pharmaceuticals (NASDAQ: AQXP)
Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on Aquinox Pharmaceuticals (NASDAQ: AQXP) today and set a price target of $22. The company’s shares opened today at $12.42.
Lee commented:
“We had the pleasure of hosting Aquinox CEO David Main for meetings with institutional investors in Boston last week. Overall, investors focused on upcoming LEADERSHIP 301 data assessing lead drug candidate rosiptor in bladder pain syndrome/interstitial cystitis (BPS/IC), and on the regulatory and competitive landscape for BPS/IC. With enrollment of the Ph3 LEADERSHIP 301 trial completed in February, AQXP remains on track to deliver top-line data in 3Q18. We reiterate our BUY rating and $22 PT. Signs Asian development and commercialization agreement with Astellas Pharma for rosiptor in IC/BPS and other indications.”
According to TipRanks.com, Lee is a 4-star analyst with an average return of 5.1% and a 47.1% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Zynerba Pharmaceuticals, and Nektar Therapeutics.
Currently, the analyst consensus on Aquinox Pharmaceuticals is Strong Buy and the average price target is $25, representing a 101.3% upside.
In a report issued on May 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $28 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
